Efficacy of cetuximab and panitumumab in oral squamous cell carcinoma cell lines: Prognostic value of MAGE-A subgroups for treatment success

Hartmann, Stefan; Kriegebaum, Ulrike; Küchler, Nora; Lessner, Grit; Brands, Roman C.; Linz, Christian; Schneider, Tim; Kübler, Alexander C.; Müller‐Richter, Urs

doi:10.1016/j.jcms.2012.12.006

Cited by 20 publications

(24 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…By contrast, MAGE-A12 was associated with an improved outcome of erlotinib administration. In a previous study by our group, MAGE-A5 and -A8 were reported as negative predictors of anti-EGFR therapy using panitumumab (15). In agreement with a recent study by our group, MAGE-A12 was correlated with a greater response to panitumumab (15).…”

Section: Discussionsupporting

confidence: 90%

“…In a previous study by our group, MAGE-A5 and -A8 were reported as negative predictors of anti-EGFR therapy using panitumumab (15). In agreement with a recent study by our group, MAGE-A12 was correlated with a greater response to panitumumab (15). Mollaoglu et al (27) previously described MAGE-A12 as a predictor of improved prognosis in oral squamous cell carcinoma.…”

Section: Discussionsupporting

confidence: 89%

“…Recently, Laban et al (14) published data indicating a marked correlation between poor prognosis in a subset of patients with head and neck cancer and the expression of MAGE-A antigens. In addition, a previous study by our group identified a correlation between MAGE-A5 and -A8 expression and poorer responses to anti-epidermal growth factor receptor (EGFR) therapy in vitro (15). Of note, MAGE-A11 expression is also correlated with poorer responses to cisplatin, 5-fluorouracil, docetaxel and paclitaxel (16).…”

Section: Introductionmentioning

confidence: 83%

“…The cell lines used in the present study (Table I) were established at the Cancer Institute of the University of Pittsburgh (Pittsburgh, PA, USA) (23). As described previously (15,24), the cells were cultured in a humidified atmosphere of 5% CO 2 /95% air at 37˚C and were fed 2-3 times per week with Dulbecco's Modified Eagle's Medium (DMEM; Life Technologies, GmbH, Darmstadt, Germany) with low glucose, 10% fetal calf serum (Life Technologies, GmbH), 1% penicillin/streptomycin (Life Technologies, GmbH) and 1% L-glutamine (Biochrom KG, Berlin, Germany).…”

Section: Methodsmentioning

confidence: 99%

“…The protocol and quantification of MAGE-A expression by RT-qPCR was conducted as previously described by our group (15,16).…”

Section: Rna Isolation and Reverse Transcription-quantitative Polymermentioning

confidence: 99%

See 4 more Smart Citations

Melanoma-associated antigen expression and the efficacy of tyrosine kinase inhibitors in head and neck cancer

et al. 2015

Self Cite

View full text Add to dashboard Cite

Abstract. Melanoma-associated antigen (MAGE) has been identified in a variety of types of cancer. The expression of several MAGE subgroups is correlated with poor prognosis and chemotherapeutic resistance. One target of chemotherapeutic treatment in head and neck cancer is the epidermal growth factor receptor (EGFR). The efficacy of tyrosine kinase inhibitors (TKI) in the context of melanoma-associated antigens is discussed in the present study. Five human squamous cell carcinoma cell lines were treated with the EGFR TKIs, erlotinib and gefitinib. The efficacy of these agents was measured using a crystal violet assay. Furthermore, the expression levels of MAGE-A1, -A5, -A8, -A9, -A11 and -A12 were determined by reverse transcription-quantitative polymerase chain reaction. The association between TKI efficacy and MAGE-A expression was analyzed by linear regression. The cell lines revealed inhomogeneous expression patterns for the MAGE-A subgroups. Four of the five cell lines demonstrated a good response to erlotinib and gefitinib. However, treatment with erlotinib induced better results than those of gefitinib, and revealed a concentration-dependent effect. The expression of MAGE-A5 and -A11 were significantly correlated with lower efficacy of erlotinib and gefitinib. By contrast, MAGE-A12 was associated with a superior response to these two drugs. One cell line, which expressed all investigated MAGE-A subgroups, was entirely resistant to the two TKIs. These results revealed a notable correlation between MAGE-A5 and -A11 and lower efficacy of EGFR TKIs. Pretreatment analysis of MAGE-A status may therefore aid improvement of chemoprevention using erlotinib and gefitinib in head and neck cancer.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionsupporting

confidence: 89%

Section: Introductionmentioning

confidence: 83%

Section: Methodsmentioning

confidence: 99%

“…The protocol and quantification of MAGE-A expression by RT-qPCR was conducted as previously described by our group (15,16).…”

Section: Rna Isolation and Reverse Transcription-quantitative Polymermentioning

confidence: 99%

See 3 more Smart Citations

Melanoma-associated antigen expression and the efficacy of tyrosine kinase inhibitors in head and neck cancer

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

Epidermal growth factor receptor (EGFR) involvement in epithelial‐derived cancers and its current antibody‐based immunotherapies

London

Gallo

2020

Cell Biology International

View full text Add to dashboard Cite

The epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein that is part of the family of tyrosine kinase receptors. The binding of EGFR to its cognate ligands leads to its autophosphorylation and subsequent activation of the signal transduction pathways involved in regulating cellular proliferation, differentiation, and survival. Accordingly, this receptor carries out both redundant and restricted functions in the germline development of mammals and in the maintenance of various adult tissues. Correspondingly, the loss of EGFR regulation results in many human diseases, with the most notable cancer. This receptor is overexpressed and/or mutated in multiple epithelial-derived tumors, and associated with poor prognosis and survival in cancer patients. Here, we discuss in detail the role of EGFR in specific epithelial-derived cancer pathologies; these include lung cancer, colorectal cancer, and squamous cell carcinomas. The development of multiple anticancer agents against EGFR diminished the progression and metastasis of tumors. Some of the most versatile therapeutic anti-EGFR agents include the monoclonal antibodies (mAbs), demonstrating success in clinical settings when used in combination with cytotoxic treatments, such as chemotherapy and/or radiation. We thus discuss the development and application of two of the most notable therapeutic mAbs, cetuximab, and panitumumab, currently utilized in various EGFR-related epithelial cancers.

show abstract

Erlotinib and gefitinib responsiveness in head and neck cancer cell lines—a comparing analysis with cetuximab

et al. 2015

View full text Add to dashboard Cite

show abstract

Efficacy of cetuximab and panitumumab in oral squamous cell carcinoma cell lines: Prognostic value of MAGE-A subgroups for treatment success

Cited by 20 publications

References 27 publications

Melanoma-associated antigen expression and the efficacy of tyrosine kinase inhibitors in head and neck cancer

Melanoma-associated antigen expression and the efficacy of tyrosine kinase inhibitors in head and neck cancer

Epidermal growth factor receptor (EGFR) involvement in epithelial‐derived cancers and its current antibody‐based immunotherapies

Erlotinib and gefitinib responsiveness in head and neck cancer cell lines—a comparing analysis with cetuximab

Contact Info

Product

Resources

About